Prevalence and risk of colorectal polyps among the Korean population under 50 years

Su Jin Jeong, MDa, Jinho Lee, MDa, Eunjoo Kim, MDb, Jun Seong Hwang, MDb, Jin Lee, MDb, Joon Hyuk Choi, MDa, Nae-Yun Heo, MDa, Jongha Park, MDa, Seung Ha Park, MDa, Tae Oh Kim, MDa, Yong Eun Park, MDa*

Abstract

Colorectal cancer is a common cancer; generally, adults aged ≥ 50 years are screened using stool occult blood tests and colonoscopy. However, colorectal adenoma and cancer have been found in patients under the age of 50, and studies on characteristics and risk factors in young patients are lacking. We evaluated the prevalence and risk factors of colorectal adenoma and cancer in young adults aged under 50 years.

We retrospectively analyzed 570 individuals aged under 50 years who underwent colonoscopy at the Haedundae Paik Hospital, Korea, from January to June 2018. Logistic regression model was used to identify the risk factors for colorectal adenoma and colorectal cancer.

The prevalence of colorectal adenoma in group of 19–29 years was 3.2% (1 of 31), 30–39 years was 13.8% (30 of 217) and in the group of 40–49 years was 21.1% (68 of 322) (P = .009). In multivariable analysis, age over 45 years (adjusted odds ratio [OR], 1.941; 95% confidence interval [CI], 1.187–3.172; P = .008) and male sex (adjusted OR, 1.711; 95% CI, 1.044–2.806; P = .033) were independent risk factors for colorectal neoplasia including cancer.

The prevalence of colorectal adenoma increases as the age increased in young adults under 50 years of age, especially after the age of 45 years, the risk of colorectal neoplasia increases; hence, early screening should be considered before the age of 50 years.

Abbreviations: BMI = body mass index, CEA = carcinoembryonic antigen, CIs = confidence intervals, CRC = colorectal cancer, LDL = low-density lipoprotein, ORs = odds ratios, SD = standard deviation

Keywords: colorectal adenoma, colorectal neoplasia, prevalence, risk factor, young adults

1. Introduction

Colorectal cancer (CRC) is a malignant tumor that occurs in the colon and rectum. According to a recent survey by Bray et al.,[1] it was the third most common carcinoma worldwide and the second most common cause of cancer death in 2018. In Korea, CRC was the second most common cancer in 2017 and the third most common cause of cancer death in 2018.[2] Genetic and environmental factors affect CRC, and risk factors for CRC include age over 50 years, dietary factors (high fat and meat intake and low dietary fiber intake), alcohol consumption, obesity, and family history of CRC.[3,4] Colonoscopy is the most powerful modality for detecting colorectal polyps and CRC. The current international guidelines recommend screening using colonoscopy from the age of 50 years for early detection of CRC and colorectal adenomatous polyps.[5] Most CRCs occur in adenomas through the traditional adenoma–carcinoma sequence.[6] Screening colonoscopy for early detection of colon polyps and polyps removal can reduce the prevalence and mortality of CRC.[7–10] Over recent decades, the prevalence and mortality of CRC in individuals aged ≥50 years have decreased, but those in individuals aged <50 years has increased.[10,11] According to the recent trend, Bailey et al.[10] predicted that in 2030, the prevalence of colon and rectal cancer will increase by 90% and 124% in individuals aged 20 to 34 years, respectively, and by 28% and 46% for individuals aged 35 to 49 years, respectively. Previous studies have reported that early-onset CRC in young adults aged under 50 years has a more advanced disease course at the time of diagnosis than that in adults aged >50 and the that prognosis is often poor.[12,13] Thus, young-onset colorectal neoplasia, including CRC and its precursors (colorectal adenoma), are of great concern. However, limited studies have assessed the prevalence and epidemiology of CRC and colorectal adenoma in younger populations.

In Korea, the clinical characteristics, related risk factors, and prevalence of early-onset CRC and colorectal adenoma in patients aged <50 years have been studied in several reports, but there have been limited related studies, and most studies have been limited to specific age groups (e.g., 20–39, 40–49, or 40–59 years).[14–17] Therefore, this study aimed to investigate the prevalence, clinical characteristics, and risk factors of early-onset colorectal adenoma and CRC in young adults aged 19 to 49 years.
2. Methods

2.1. Study population

This study enrolled 668 patients aged ≤50 years who underwent colonoscopy between January and June 2018 at Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea. Patients with no clinical data or clinical records available due to incomplete examination or poor bowel preparation (n = 7), foreigners (n = 65), patients diagnosed with inflammatory bowel disease (e.g., ulcerative colitis or Crohn disease) or intestinal tuberculosis prior to colonoscopy (n = 21), and patients diagnosed with other diseases such as neuroendocrine tumor and lymphoma on colonoscopy (n = 5) were excluded. Also, polyposis caused by genetic factors such as familial polyposis was excluded. Poor bowel preparation was defined as “presence of large amounts of solid fecal matter, precluding a satisfactory study; unacceptable preparation; <90% visibility of the mucosa.” Finally, 570 patients were included in the study (Fig. 1). This study was performed in accordance with the ethical guidelines of the Declaration of Helsinki 1975 and approved by the Institutional Review Board of Haeundae Paik Hospital (HIPRB File No: 2020-07-017). The requirement for informed consent was waived because only de-identified data were retrospectively assessed.

2.2. Study procedures and definitions.

2.2.1. Colonoscopy. All colonoscopies were performed by experienced board-certified endoscopists using standard colonoscopes (Evis Luctera CV-260SL or Evis Luctera CV-290; Olympus Medical Systems, Tokyo, Japan). Bowel preparation was performed using a standard protocol with polyethylene glycol lavage or sodium phosphate. The polyp location, size, number, and morphology were recorded during colonoscopy. The polyp location was categorized as the right colon, left colon, and both sides. The right colon was defined as the cecum, ascending colon, and transverse colon, and the left colon was defined as the descending colon, sigmoid colon, and rectum. The size of each polyp was estimated using open 8-mm biopsy forceps (FB-230U; Olympus Medical Systems, Tokyo, Japan). The polyp morphology was described according to the Paris classification. All detected polyps were removed endoscopically using either cold forceps biopsy or endoscopic mucosal resection/endoscopic submucosal dissection.

2.2.2. Diagnosis of colorectal polyps. All detected polyps were histopathologically evaluated according to the World Health Organization criteria. In the histopathological examination of polyp lesions, hyperplastic polyps, chronic nonspecific inflammation, and benign lymphocytic hyperplasia were defined as normal groups. In the adenoma group, tubular adenomas measuring ≥10 mm in diameter, villous adenomas, adenomas with ≥25% change in the villous structure, tubulovillous adenomas, sessile serrated adenomas, and adenomas with high-grade dysplasia were defined as advanced adenomas. Adenomatous polyps were defined as tubular adenoma <10 mm and advanced adenoma group. CRC was defined as histopathologically confirmed adenocarcinoma. Colorectal neoplasia was defined as adenomatous polyps and CRC, and advanced neoplasia was defined as the advanced adenoma group and CRC.

2.3. Measurements and risk factor assessment

To investigate the medical history and drugs used in combination, endoscopists asked questions or administered self-administered questionnaires were used prior to colonoscopy. During colonoscopy, the presence of symptoms related to colon and other comorbid diseases (e.g., diabetes, hypertension, dyslipidemia, liver diseases, hematologic diseases, cardiologic diseases, and other cancers), surgical history, and drug use were examined. Body mass index was calculated as weight (in

![Figure 1. Subjects enrollment.](image-url)
kilograms) divided by height (in meters) squared. Blood samples for biochemical and metabolic parameters were obtained after overnight fasting lasting for at least 8 hours. Fasting plasma glucose, total cholesterol, low-density lipoprotein cholesterol, triglyceride, and high-density lipoprotein cholesterol levels were measured. Patients who were taking antihypertensive drugs or had increased blood pressure on the day of the test (blood pressure ≥130/85 mm Hg) were considered as having hypertension, and those with elevated triglyceride levels (≥150 mg/dL) and low-density lipoprotein cholesterol levels (≥130 mg/dL) were considered as having dyslipidemia. Participants diagnosed with CRC underwent additional investigations to assess tumor markers and carcinoembryonic antigen (CEA) levels. In participants who also underwent esophagogastroduodenoscopy on the day of colonoscopy, the presence of Helicobacter pylori infection was evaluated. H. pylori infection was diagnosed by histological identification using a modified Giemsa stain or rapid urease test during gastroscopy.

2.4. Statistical analysis
Variables are presented as mean ± standard deviation or n (%). The baseline characteristics were compared using independent Student t-test or ANOVA test, and the Mann–Whitney test for continuous variables and the χ² test or Fisher exact test for categorical variables, as appropriate. Basic characteristics were compared according to age ≥45 years and <45 years and 10-year age groups. Independent predictors of colorectal adenoma and CRC in patients who underwent colonoscopy were analyzed using logistic regression analysis. Odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were calculated. Data analysis was performed using SPSS (version 25.0; IBM Corp., Armonk, NY). Furthermore, we expressed the difference between the pathological results of polyps according to 5-year age groups by group graphs using GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA). A P value <.05 was considered statistically significant.

3. Results
3.1. Baseline characteristics and polyps of study participants
3.1.1. 19 to 29 versus 30 to 39 versus 40 to 49 years. From January to June 2018, 570 patients aged <50 years who underwent colonoscopy were analyzed. There were 31 (5.4%) patients aged 19 to 29 years, 217 (38.1%) patients aged 30 to 39 years, and 322 (56.5%) patients aged 40 to 49 years. The baseline characteristics of the included patients are shown in Table 1. Younger patients (19–29 years) were more likely to undergo colonoscopy due to symptoms than colonoscopy for either screening, other cancer work up or previous polyp (71.0% vs 19.4% vs 25.8%; P = .015). Patients aged ≥30 years had more underlying diseases such as hypertension (0% vs 0.9% vs 4.3%; P = .038), liver disease especially fatty liver (0% vs 23.5% vs 20.8%; P = .001), and dyslipidemia (9.7% vs 38.7% vs 39.8%; P = .004) than patients aged <30 years (Table 1).

The polyp detection rate increased with the increasing age (9.7% vs 35.9% vs 40.7%, 19–29, 30–39, 40–49, respectively; P = .003; P = .003), and the ratio of tubular adenomas < 10 mm with low-grade dysplasia was higher (3.2% vs 13.8% vs 21.1%; P = .009). The prevalence of advanced adenomas increased with the increasing age (0% vs 0.5% vs 1.6%; P = .400), and the location of advanced adenomas tended to be higher in the right colon than in other locations. CRC was only found in patients aged ≥40 years (0% vs 0% vs 1.6%; P = .143; Table 2). One out of 5 patients with CRC was diagnosed with CRC at our hospital, and additional evaluation and treatment were performed at other hospitals, so the final stage could not be confirmed. Of the remaining 1, 1 was identified as stage IIIA and 3 as stage IV. The CEA values of patients diagnosed with CRC were 2.52 ± 1.34 (ng/mL), which was within the normal range for most of them (data not shown).

3.1.2. Under 45 vs >45 years. There were 422 (74.0%) patients aged 19 to 44 years and 148 (26.0%) patients aged 45 to 49 years. The baseline characteristics of patients in both groups are shown in Table 3. The prevalence of diabetes (2.1% vs 3.5%...
vs 6.1%; \( P = .018 \) and other malignancies (2.6% vs 8.8%; \( P = .001 \)) was significantly higher in patients aged \( \geq 45 \) years than in those aged \( <45 \) years. A total of 90 subjects were tested for \textit{H. pylori} infection. There was no significant difference in \textit{H. pylori} infection between groups, but about 50% of the 90 patients tested in both groups had \textit{H. pylori} infection (Table 3).

The polyp detection rate was similar between patients aged \( <45 \) and \( \geq 45 \) years (36.7% vs 38.5%; \( P = .699 \)); however, colorectal adenomas \( <10 \text{ mm} \) with low-grade dysplasia were significantly more common in patients aged \( \geq 45 \) years than in patients aged \( <45 \) years (14.9% vs 24.3%; \( P = .009 \)). Furthermore, all polyps over adenomas, except chronic nonspecific inflammations, hyperplastic polyps, were significantly higher in patients aged \( \geq 45 \) years than in patients aged \( <45 \) years (15.4% vs 23.6%; \( P = .023 \)). In addition, the rate of CRC was significantly higher in patients aged \( \geq 45 \) years than in patients aged \( <45 \) years (24.2% vs 27.0%; \( P = .006 \); Table 4). For detailed differences, we compared the histological results of polyps by dividing the age by 5 years. Hyperplastic polyps and tubular adenomas were significantly different when analyzed at 5-year intervals, and tubular adenomas significantly increased with age (\( P = .017 \); Fig. 2).

### 3.3. Risk factors of colorectal neoplasia

Univariate and multivariable analyses were performed to determine the risk factors for colorectal adenoma and CRC in patients aged \( \leq 50 \) years who underwent colonoscopy (Table 5). In univariate logistic regression analysis, age \( \geq 45 \) years (OR, 1.930; 95% CI, 1.230–3.028; \( P = .004 \)) and colonoscopy due to bowel habit change (OR, 0.339; 95% CI, 0.119–0.971; \( P = .044 \)) were identified as significant factors for colorectal neoplasia. In multivariable analysis, after adjusting for body mass index, fasting glucose levels and presence of hypertension, diabetes, and other malignancies, age over 45 years (adjusted OR, 1.941; 95% CI, 1.187–3.172; \( P = .008 \)) and male sex (adjusted OR, 1.711; CI, 1.044–2.806; \( P = .033 \)) were independent risk factors for colorectal neoplasia.

### 4. Discussion

This study is the one on the prevalence and risk factors of colorectal adenoma and CRC in a young population aged 19 to 49 years in Korea. Although several studies on the prevalence and risk factors of colorectal adenoma and CRC have been conducted in individuals aged \( \leq 50 \) years, most studies were mainly included individuals aged 40 to 49 years. Only a few recent Korean studies have investigated the prevalence and risk factors of colorectal adenoma and CRC in individuals aged 20 to 39 years.[14,15] In our study, the prevalence of colorectal adenoma \( <10 \text{ mm} \) in patients aged 19 to 29, 30 to 39, and 40 to 49 years were 3.2%, 13.8%, and 21.1%, respectively. The prevalence of overall neoplasia and advanced neoplasia, including advanced adenoma and CRC, were 3.2% and 0%, 14.3% and 0.5%, and 24.2% and 3.1%, respectively. These rates were comparable to those reported in some Korean studies or slightly higher than those reported in previous studies.[14–17,22–24] It is possible that the prevalence of advanced neoplasia in our study was higher (3.1%) than that reported in previous studies (2.4%–2.9%) in individuals aged 40 to 49 years in Korea because this study included both asymptomatic and symptomatic participants.[16,17]

According to Kang et al,[23] the symptomatic group had a higher prevalence of advanced colorectal adenomas than the screening or surveillance group. However, there was no significant difference in the prevalence of advanced colorectal adenomas between subgroups of the alarm and nonalarm categories (11.7% vs 9.7%, \( P = .056 \)).

### Table 2

Characteristics of polyps in 3 groups of subjects divided by age.

| Variables  | 19 to 29 y (n = 31, 5.4%) | 30 to 39 y (n = 217, 38.1%) | 40 to 49 y (n = 322, 56.5%) | \( P \text{ value}^* \) |
|------------|---------------------------|-----------------------------|-----------------------------|--------------------------|
| Polyps     | 3 (9.7)                   | 78 (35.9)                   | 131 (40.7)                  | .003                     |
| Location   |                           |                             |                             |                          |
| Right colon| 0 (0)                     | 34 (43.6)                   | 57 (43.5)                   | .062                     |
| Left colon | 3 (100.0)                 | 32 (41.0)                   | 41 (31.3)                   |                          |
| Both       | 0 (0)                     | 12 (15.4)                   | 33 (25.2)                   |                          |
| Morphology |                           |                             |                             | .096                     |
| Iss        | 2 (66.7)                  | 73 (93.6)                   | 112 (85.5)                  |                          |
| Ip         | 0 (0)                     | 2 (2.6)                     | 5 (3.8)                     |                          |
| Isp        | 1 (33.3)                  | 1 (1.3)                     | 6 (4.6)                     |                          |
| Iia        | 0 (0)                     | 2 (2.6)                     | 8 (6.1)                     |                          |
| Size (mm)  | 9.67 ± 9.07               | 4.27 ± 2.43                 | 5.84 ± 8.33                 | .234                     |
| Number (n) | 0.11 ± 0.32               | 0.76 ± 1.03                 | 0.95 ± 1.43                 | .659                     |
| Pathologic findings |          |                             |                             |                          |
| CNSI       | 0 (0)                     | 15 (6.9)                    | 32 (9.9)                    | .105                     |
| HP         | 2 (6.5)                   | 47 (21.7)                   | 64 (20.1)                   | .140                     |
| TA, LGD \( <10 \text{ mm} \) | 1 (3.2) | 30 (13.8)  | 68 (21.1)  | .009                     |
| TA, LGD \( \geq 10 \text{ mm} \) | 0 (0) | 1 (0.5) | 1 (0.3) | .905                     |
| TVA/VA     | 0 (0)                     | 0 (0)                       | 1 (0.3)                     | .680                     |
| SSA        | 0 (0)                     | 0 (0)                       | 3 (0.9)                     | .313                     |
| TA, HGD    | 0 (0)                     | 0 (0)                       | 1 (0.3)                     | .680                     |
| Adenomatous polyps | 1 (3.2) | 30 (13.8) | 69 (21.4) | .007                     |
| Advanced adenomas | 0 (0) | 1 (0.5) | 5 (1.6) | .400                     |
| Location   |                           |                             |                             | .301                     |
| Right colon| 0 (0)                     | 0 (0)                       | 3 (60.0)                    |                          |
| Left colon | 0 (0)                     | 1 (100.0)                   | 1 (20.0)                    |                          |
| Both       | 0 (0)                     | 0 (0)                       | 1 (20.0)                    |                          |
| Colon cancer | 0 (0)                 | 0 (0)                       | 5 (1.6)                     | .143                     |

Data are expressed as mean±standard deviation (SD) or n (%).

CNSI = chronic nonspecific inflammation, LGD = low-grade dysplasia, SSA = sessile serrated adenoma, TA = tubular adenoma, TVA = tubulovillous adenoma, VA = villous adenoma.

\* \( P \) value for comparing patients with three groups divided by age.

† Advanced adenomas were found in 5 subjects, in one subject, one TVA and one TA, HGD were detected respectively. A total of 6 advanced adenomas were detected in the age of 40- to 49-year group.
In this study, the prevalence of colorectal adenoma and CRC significantly increased in individuals aged 45 to 49 years compared to those aged 19 to 44 years (15.4% vs 23.6%, \( P = .023 \) and 0.2% vs 2.7%, \( P = .006 \)). In a large-scale Chinese cohort study by Chen et al.,\(^{26}\) on colorectal adenoma in the population under the age of 50, the detection rate of colored adenoma increased significantly as the age increased, and in particular, the detection rate increased significantly over the age of 45. In that study by Chen et al., the adenoma detection rate was found to be somewhat lower than in our study, and maybe the reason is that serrated polypl was analyzed separately from adenoma. In the Italian study by Agazzi et al.,\(^{27}\) age as a continuous variable was also associated with the presence of adenomas (incidence rate ratio 1.06; 95% CI, 1.03–1.09; \( P < .001 \)). And, over 40 years of age was a major risk factor for both adenoma and early-onset CRC (OR 2.25; 95% CI, 1.35–3.73; \( P = .002 \)).

Most major guidelines recommend starting screening at the age of 50 years in adults with no family history.\(^{28–32}\) However, the guideline of the American Cancer Society in 2018 recommended that a screening test be performed according to patient preference at the age of 45 years (qualified recommendation).\(^{33}\) The evidence for starting screening test at age 45 in the American Cancer Society guidelines is based on several studies.\(^{34}\) In a recent modeling analysis using large-scale epidemiological data in the United States, when a microsimulated model of a 40-year-old adult was applied in 2015, colonoscopy every 10 years starting at the age of 45 years, sigmoid colonoscopy every 5 years, CT colonoscopy every 5 years, and annual fecal immunochemistry tests were considered effective.\(^{35}\) In the United States, Canada, Australia, Denmark, New Zealand, and the United Kingdom, the incidence of CRC in individuals aged <50 years, which is not the age required for screening, is increasing. Studies conducted in Asian countries also show an increase in the incidence of CRC in individuals aged <50 years in Taiwan, Japan, and Hong Kong.\(^{36–40}\) The studies argue that the age at which screening starts should be lowered because of the increase in young CRC patients aged under 50 years. In Korea, the incidence of CRC has been decreasing since 2010 in all age groups, except \( \geq 85 \) year and 25 to 29 year age groups.\(^{41}\) In Korea, it is unclear why the incidence of CRC has decreased in recent years in individuals aged <50 years, but compared to other countries, colonoscopy and polypectomy are often performed in Korea even at a young age because access to medical care is relatively good and the cost is inexpensive. Hence, the incidence of CRC appears to have been decreased in individuals aged <50 years, similar to individuals aged \( \geq 50 \) years.

Several studies on risk factors of CRC have been conducted in the United States. Risk factors for early-onset CRC include genetic factors, male, race, early antibiotic exposure, diabetes, and controllable risk factors such as diet, obesity, smoking, alcohol use, and meat consumption.\(^{42,43}\) However, just as the difference in CRC incidence varies from country to country, risk factors may not be the same in the United States and Korea because of race, economic status, and region. Nevertheless, it was shown that the risk of CRC was high for those over 45 years of age and men. In a recent large-scale study using data from the National Insurance Corporation in Korea, the age for appropriate CRC screening using Youden index was studied, and an age of 45 years was considered the most appropriate.\(^{44}\) By lowering the starting age of CRC screening test, it is possible to reduce the incidence and mortality of CRC in young adults, thereby improving the quality of life and reducing social costs. In addition, the present intervention has an effect on increasing the screening rate of CRC in adults aged \( \geq 50 \) years. However, if the age for screening test is lowered to 45 years, the screening test rate of individuals at a high risk for colon cancer can be lowered due to the limited number of colonoscopies; and, there is a problem of increasing medical expenses due to the increase in the total number of subjects who underwent colonoscopy. Another major problem is that there is no direct clinical study on the effect of starting colon cancer screening at the age of 45 years. Therefore, when additional analysis were performed on 50- to 55-year-old patients who underwent colonoscopy to compare with 45- to 50-year-old patients (data not shown), it

### Table 3

| Variables                  | 19 to 44 y (n = 422, 74.0%) | 45 to 49 y (n = 148, 26.0%) | \( P \) value* |
|----------------------------|-----------------------------|-----------------------------|----------------|
| Male sex                   | 219 (51.9)                  | 70 (47.3)                   | .336           |
| Median age (y)             | 37.6 ± 4.9                  | 47.0 ± 1.4                  | <.001          |
| BMI (kg/m²)                | 23.8 ± 3.9                  | 23.2 ± 3.6                  | .142           |
| Fasting glucose (mg/dL)    | 91.5 ± 18.7                 | 94.5 ± 25.0                 | .149           |
| Cause of colonoscopy       |                             |                             |                |
| Symptoms                   | 99 (23.5)                   | 48 (32.4)                   | .402           |
| Hematochezia, anemia       | 28 (28.3)                   | 8 (16.7)                    | .076           |
| Dyspepsia, abdominal pain  | 36 (36.4)                   | 20 (41.7)                   | .719           |
| Bowel habit changes        | 32 (32.3)                   | 17 (35.4)                   |                |
| Weight loss                | 3 (3.0)                     | 3 (6.3)                     |                |
| Other work up or previous polyp | 15 (3.6)               | 8 (5.4)                     |                |
| Screening                  | 308 (73.0)                  | 92 (62.2)                   |                |
| Underlying disease         |                             |                             |                |
| Hypertension               | 9 (2.1)                     | 7 (4.7)                     | .100           |
| Diabetes                   | 9 (2.1)                     | 9 (6.1)                     | .018           |
| Liver disease              |                             |                             | .076           |
| Fatty liver                | 96 (22.7)                   | 22 (14.9)                   |                |
| Viral hepatitis            | 5 (1.2)                     | 5 (3.4)                     |                |
| Others†                    | 4 (0.9)                     | 2 (1.4)                     |                |
| Cardiologic disease        | 2 (0.5)                     | 3 (2.0)                     | .081           |
| Other malignancy           | 11 (2.6)                    | 13 (8.8)                    | .001           |
| Dyslipidemia               | 161 (38.2)                  | 54 (36.5)                   | .719           |
| Helicobacter pylori infection (n = 90)‡ | 27 (47.4)             | 18 (54.5)                   | .512           |

Data are expressed as mean ± standard deviation (SD) or n (%).

BMI = body mass index.

\( * \) P value for comparing patients with two groups divided by age.

† Others: alcoholic hepatitis, Wilson’s disease, toxic hepatitis, cryptogenic LC

‡ A total of 90 subjects were tested for Helicobacter pylori infection. A total of 45 subjects were identified as positive for Helicobacter pylori infection.
Table 4
Characteristics of polyps in 2 groups of subjects divided by age the age of 45.

| Variables                        | 19 to 44 y (n = 422, 74.0%) | 45 to 49 y (n = 148, 26.0%) | P value* |
|----------------------------------|-----------------------------|----------------------------|----------|
| Polyps                           | 155 (36.7)                  | 57 (38.5)                  | .699     |
| Location                         |                             |                           | .537     |
| Right colon                      | 70 (45.2)                   | 21 (36.8)                  |          |
| Left colon                       | 54 (34.8)                   | 22 (38.6)                  |          |
| Both                             | 31 (20.0)                   | 14 (24.6)                  |          |
| Morphology                       |                             |                           | .686     |
| ls                               | 139 (89.7)                  | 48 (84.2)                  |          |
| lp                               | 5 (3.2)                     | 3 (5.3)                    |          |
| lsp                              | 5 (3.2)                     | 2 (3.5)                    |          |
| llia                             | 6 (3.9)                     | 4 (7.0)                    |          |
| Size (mm)                        | 4.59 ± 2.72                 | 7.30 ± 12.22               | .103     |
| Number (n)                       | 0.79 ± 1.10                 | 0.94 ± 1.65                | .334     |
| Pathologic findings              |                             |                           |          |
| CNSI                             | 35 (8.3)                    | 12 (8.1)                   | .944     |
| HP                               | 90 (21.5)                   | 23 (15.5)                  | .120     |
| TA, LGD < 10 mm                  | 63 (14.9)                   | 36 (24.3)                  | .009     |
| TA, LGD ≥ 10 mm                  | 1 (0.2)                     | 1 (0.7)                    | .437     |
| TVA/VA                           | 0 (0)                       | 1 (0.7)                    | .091     |
| SSA                              | 0 (0)                       | 1 (0.7)                    | .091     |
| TA, HGD                          | 2 (0.5)                     | 1 (0.7)                    | .770     |
| Adenomatous polyps               | 65 (16.4)                   | 35 (23.6)                  | .023     |
| Location (n = 100)               |                             |                           | .610     |
| Right colon                      | 24 (37.5)                   | 11 (31.4)                  |          |
| Left colon                       | 24 (37.5)                   | 12 (34.3)                  |          |
| Both                             | 16 (25.0)                   | 12 (34.3)                  |          |
| Morphology (n = 99)              |                             |                           | .475     |
| ls                               | 59 (92.2)                   | 30 (85.7)                  |          |
| lp                               | 1 (1.6)                     | 0 (0)                      |          |
| llsp                             | 3 (4.7)                     | 3 (8.6)                    |          |
| llia                             | 1 (1.6)                     | 2 (5.7)                    |          |
| Advanced adenomas                | 3 (0.7)                     | 3 (2.0)                    | .177     |
| Location (n = 6)                 |                             |                           | .513     |
| Right colon                      | 2 (66.7)                    | 1 (33.3)                   |          |
| Left colon                       | 1 (33.3)                    | 1 (33.3)                   |          |
| Both                             | 0 (0)                       | 1 (33.3)                   |          |
| Colon cancer                     | 1 (0.2)                     | 4 (2.7)                    | .006     |

Data are expressed as mean ± standard deviation (SD) or n (%).
CNSI = chronic nonspecific inflammation, HGD = high-grade dysplasia, HP = hyperplastic polyp, LGD = low-grade dysplasia, SSA = sessile serrated adenoma, TA = tubular adenoma, TVA = tubulovillous adenoma, VA = villous adenoma.
*
P value for comparing patients with 2 groups divided by age.

Figure. 2. Comparison of histopathological findings by age. HPs (P = .027) and tubular adenomas (P = .017) show significant differences by age at 5-year intervals. CNSI = chronic nonspecific inflammation, HGD = high-grade dysplasia, HP = hyperplastic polyp, LGD = low-grade dysplasia, SSA = sessile serrated adenoma, TA = tubular adenoma, TVA = tubulovillous adenoma, VA = villous adenoma.
shown that the polyp incidence was significantly increased at the age of 50 to 55 (39, 26.4% vs 81, 67.5%; \( P = .001 \)), but the CRC incidence showed similar rates (4, 2.7% vs 3, 1.9%; \( P = .614 \)). This shows that the occurrence of CRC at the age of 45 and 50 cannot be ignored. Although other risk factors were not compared, further studies are needed.

Our study has several limitations. First, this was a retrospective study in a single-center hospital; hence, selection bias may have occurred. In addition, the number of subjects enrolled in this retrospective study was small and the period of subject selection was short, resulting in selection bias. Previous large-scale studies have shown that male sex, smoking status, alcohol consumption, obesity, abdominal obesity, and metabolic syndrome are risk factors for the development of colorectal neoplasia in young adults aged <50 years.\(^{14–17}\) However, in our study, age over 45 years old and male sex were significant risk factors of colorectal neoplasia. In addition to the medical records of asymptomatic participants who underwent colonoscopy at the Health Promotion Center, those of symptomatic participants who underwent colonoscopy through the department of gastroenterology were reviewed retrospectively, and there were limitations on the investigation of accurate previous medical history, family history of CRC and other cancers in 185 countries. CA: A Cancer J Clin. 2018;68:394–424.

\( \text{BMI} = \text{body mass index}, \ CI = \text{confidence interval}, \ OR = \text{odds ratio}. \)

### Table 5

| Variable                        | Univariate analysis | Multivariable analysis |
|---------------------------------|---------------------|-----------------------|
|                                 | OR (95% CI)        | \( P \) value         | Adjusted OR (95% CI) | \( P \) value |
| Male sex                        | 1.512 (0.984–2.322) | .059                  | 1.711 (1.044–2.806)  | .033         |
| Age over 45 y                   | 1.930 (1.230–3.028) | .004                  | 1.941 (1.187–3.172)  | .008         |
| Obesity (BMI ≥ 25 kg/m\(^2\))   | 1.090 (0.697–1.703) | .706                  | 0.795 (0.470–1.343)  | .391         |
| Fasting glucose                 | 1.003 (0.993–1.013) | .602                  | 1.001 (0.989–1.014)  | .842         |
| Cause of colonoscopy            |                     |                       |                      |
| Screening                       | 1.0 (ref.)          |                       | 1.0 (ref.)           |              |
| Hematochezia, anemia            | 0.477 (0.164–1.388) | .174                  | 0.466 (0.134–1.620)  | .230         |
| Dyspepsia, abdominal pain       | 0.731 (0.344–1.593) | .415                  | 1.170 (0.512–2.673)  | .709         |
| Bowel habit changes             | 0.539 (0.119–0.971) | .944                  | 0.459 (0.152–1.384)  | .166         |
| Weight loss                     | 0.764 (0.088–6.627) | .807                  | 0.488 (0.054–4.395)  | .522         |
| Other cancer work up or previous polyp | 0.804 (0.266–2.428) | .699 | 1.088 (0.329–3.594)  | .890         |
| Underlying disease              |                     |                       |                      |
| Hypertension                    | 2.758 (0.979–7.764) | .055                  | 1.874 (0.495–7.091)  | .355         |
| Diabetes                        | 1.735 (0.605–4.976) | .306                  | 1.038 (0.271–3.974)  | .956         |
| Liver disease                   | 1.021 (0.620–1.679) | .936                  |                       |              |
| Cardiologic disease             | 1.108 (0.73–10.017) | .927                  |                       |              |
| Other malignancy                | 1.756 (0.714–4.318) | .220                  | 1.242 (0.444–4.378)  | .680         |
| Dyslipidemia                    | 1.240 (0.806–1.908) | .328                  |                       |              |

5. Conclusion

Colorectal adenoma and CRC may occur in young adults aged under 50 years, especially in those aged over 45 years. Based on the results of previous studies and clinical studies to be implemented in the future, of CRC screening from the age of 45 years, we suggest lowering the age at which screening is conducted.

### Author contributions

Guarantor of the article: Y.E.P.
Acquisition of data; analysis and interpretation of data; drafting of the manuscript: S.J.J.
Acquisition of data; study concept and design: J.L.
Study concept and design; critical revision of the manuscript for important intellectual content: E.K., J.S.H., J.L., J.H.C., N.-Y.H., J.P., S.H.P., T.O.K.
Acquisition of data; study concept and design; critical revision of the manuscript for important intellectual content: Y.E.P.
All authors approved the final version of the article, including the authorship list.

### References

[1] Bray F, Feeney J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2018;68:394–424.

[2] National Cancer Information Center. Available at: https://www.cancer.go.kr. [access date October 8 2020].

[3] Willett W. The search for the causes of breast and colon cancer. Nature. 1989;338:389–94.

[4] Kim D-H. Risk factors of colorectal cancer. J Korean Soc Coloproctol. 2009;6:83:356–62.

[5] Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570–95.

[6] Jass J. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113–30.

[7] Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369:1095–105.

[8] Baxter NN, Goldwasser MA, Passat LF, et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150:1–8.

[9] Zauber AG, Winawer SJ, O’Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:867–96.
Jeong et al. • Medicine (2022) 101:27

[10] Bailey CE, Hu C-Y, You YN, et al. Increasing disparities in the age-related incidence of colon and rectal cancers in the United States, 1973-2010. JAMA Surg. 2015;150:17–22.

[11] Jung YS. Is colorectal cancer screening necessary before 50 years of age? Intest Res. 2017;15:550–1.

[12] O’connell JB, Maggard MA, Liu JH, et al. Rates of colon and rectal cancers are increasing in young adults. Am Surg. 2003;69:866–72.

[13] You YN, Xing Y, Feng BW, et al. Young-onset colorectal cancer: is it time to pay attention? Arch Intern Med. 2012;172:287–9.

[14] Kwak JY, Kim KM, Yang HJ, et al. Prevalence of colorectal adenomas in asymptomatic young adults: a window to early intervention? Scand J Gastroenterol. 2016;51:731–8.

[15] Kim NH, Jung YS, Yang H-J, et al. Prevalence of and risk factors for colorectal neoplasia in asymptomatic young adults (20–39 years old). Clin Gastroenterol Hepatol. 2019;17:115–22.

[16] Koo JE, Kim KJ, Park HW, et al. Prevalence and risk factors of advanced colorectal neoplasms in asymptomatic Korean people between 40 and 49 years of age. J Gastroenterol Hepatol. 2017;32:98–105.

[17] Chung SJ, Kim YS, Yang SY, et al. Prevalence and risk of colorectal adenoma in asymptomatic Koreans aged 40–49 years undergoing screening colonoscopy. J Gastroenterol Hepatol. 2010;25:519–25.

[18] Soejoso A, Kobayashi A, Jamali E, et al. A randomized single-blind trial of standard diet versus fiber-free diet with polyethylene glycol electrolyte solution for colonoscopy preparation. Endoscopy. 2010;42:633–8.

[19] Vakil N. Measurement of lesions by endoscopy: an overview. Endoscopy. 1995;27:694–7.

[20] Lambert R. Endoscopic classification review group. Update on the Paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy. 2005;37:570–8.

[21] Hamilton SR, Aaltonen LA. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press; 2000.

[22] Park H-W, Byeon J-S, Yang S-K, et al. Colorectal neoplasm in asymptomatic average-risk Koreans: the KASID prospective multicenter colonoscopy survey. Gut Liver. 2009;3:35–40.

[23] Kim HS, Baik SJ, Kim KH, et al. Prevalence and risk factors of colorectal adenoma in 14,932 Koreans undergoing screening colonoscopy. Korean J Gastroenterol. 2013;62:104–10.

[24] Choe JW, Chang HS, Yang SK, et al. Screening colonoscopy in asymptomatic average-risk Koreans: the KASID prospective multicenter colonoscopy survey. Gut Liver. 2009;3:35–40.

[25] Kang H, Yang Y, Que J, et al. Incidence and distribution of advanced colorectal adenomas in patients undergoing colonoscopy for screening, surveillance, and symptoms. Cancer Manag Res 2018;10:3875–80.

[26] Chen Z, Hu J, Zheng Z, et al. Location of colorectal adenomas and serrated polyps in patients under age 50. Int J Colorectal Dis. 2019;34:2201–4.

[27] Agazzi S, Lentz MV, Klersy C, et al. Incidence and risk factors for pre-neoplastic and neoplastic lesions of the colon and rectum in patients under 50 referred for colonoscopy. Eur J Intern Med. 2021;87:36–43.

[28] Bibbins-Domingo K, Grossman D, Curry S, et al. Screening for colorectal cancer: U.S. preventive services task force recommendation statement. JAMA. 2016;315:2564–75.

[29] Wilk TJ, Harris RP, Qaseem A. Screening for cancer: advice for high-value care from the American College of Physicians. Ann Intern Med. 2015;162:718–25.

[30] Lundsberg-Vogelhaar I, Karsa L. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition – Introduction. Endoscopy. 2012;44:S15–30.

[31] Care CTFoPH. Recommendations on screening for colorectal cancer in primary care. CMAJ. 2016;188:340–8.

[32] Helsingin LM, Vandvik PO, Jodal HC, et al. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. BMJ. 2019;367:l55315.

[33] Wolf AM, Fontham ET, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA: A Cancer J Clin. 2018;68:250–81.

[34] Knudsen A, Zuber A, Rutter C, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US preventive services task force. JAMA. 2016;315:2595–609.

[35] Peterse EF, Meester RG, Siegel RL, et al. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: microsimulation analysis I to inform the American Cancer Society Colorectal Cancer Screening Guideline. Cancer. 2018;124:2964–73.

[36] Brenner DR, Ruan Y, Shaw E, et al. Increasing colorectal cancer incidence trends among younger adults in Canada. Prev Med. 2017;105:345–9.

[37] Young JP, Win AK, Rosty C, et al. Rising incidence of early-onset colorectal cancer in Australia over two decades: report and review. J Gastroenterol Hepatol. 2015;30:6–13.

[38] Siegel RL, Fedewa SA, Anderson WF, et al. Colorectal cancer incidence patterns in the United States, 1974–2013. JNCI: J Natl Cancer Inst. 2017;109:djw322.

[39] International Agency for Research on Cancer. List of Classifications by International Agency for Research on Cancer. Volume 1 to 123. Lyon: International Agency for Research on Cancer. Available at: https://monographs.iarc.fr/wp-content/uploads/2018/07/Table4.pdf. [access date October 8, 2020].

[40] Sung JJ, Chiu H-M, Jung K-W, et al. Increasing trend in young-onset colorectal cancer in Asia: more cancers in men and more rectal cancers. Am J Gastroenterol. 2019;114:322–9.

[41] Shin A, Jang D, Choe S, et al. Colorectal cancer epidemiology in Korea. J Korean Med Assoc. 2019;62:407–15.

[42] Low EE, Demb J, Liu L, et al. Risk factors for early-onset colorectal cancer. Gastroenterology. 2020;159:492–501.e7.

[43] Gaussen V, Dormablser D, Anand S, et al. Risk factors associated with early-onset colorectal cancer. Clin Gastroenterol Hepatol. 2020;18:2752–2759.e2.

[44] Choi YJ, Lee DH, Han KD, et al. Optimal starting age for colorectal cancer screening and diagnosis. First Edition – Introduction. Endoscopy. 2012;44:S15–30.

[45] Care CTFoPH. Recommendations on screening for colorectal cancer in primary care. CMAJ. 2016;188:340–8.

[46] Helsingin LM, Vandvik PO, Jodal HC, et al. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. BMJ. 2019;367:l55315.

[47] Wolf AM, Fontham ET, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA: A Cancer J Clin. 2018;68:250–81.